Microvascular Dysfunction in Acute Myocardial Infarction (AMI) and Its Relation to Outcome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01538303|
Recruitment Status : Unknown
Verified July 2012 by Catharina Ziekenhuis Eindhoven.
Recruitment status was: Recruiting
First Posted : February 24, 2012
Last Update Posted : July 10, 2012
|Condition or disease|
|ST Segment Elevation Myocardial Infarction|
In acute myocardial infarction, early restoration of epicardial and myocardial blood flow is of paramount importance to limit infarct size and create optimum conditions for favorable long-term outcome.
Presently, restoration of epicardial blood flow is preferably obtained by primary percutaneous coronary intervention (PPCI). PPCI is the treatment of choice for patients with acute myocardial infarction who can be admitted sufficiently fast to a hospital equipped for this type for treatment.
Successful restoration of epicardial blood flow by PPCI is possible in approximately 90% of all patients. Nevertheless, in a number of these patients myocardial hypoperfusion persists due to moderate or severe microvascular dysfunction.
The terminology "no reflow" is often used for this condition. Microvascular thromboembolism, spasm, or intramyocardial oedema are suggested to be responsible for this condition and probably all of these three phenomena play a role. Besides that, inflammatory response of the myocardium can be involved with neutrophil plugging of the capillaries, further compromising restoration of normal myocardial blood flow and function.
It is well known that in patients in whom myocardial reperfusion is absent or limited, despite adequate epicardial reperfusion, prognosis is poor and more severe left ventricular dysfunction can be expected in comparison to those patients in whom also microvascular reperfusion after PPCI is restored. Therefore, it is beyond doubt that knowledge about the actual state of the microvasculature and myocardial (re)perfusion shortly after PPCI, is important from a prognostic point of view.
Moreover, if microvascular reperfusion is still limited immediately after myocardial infarction, but recovers quickly in the days thereafter, this might have important implications for long-term prognosis.
Lastly, knowledge about microvascular reperfusion in the acute phase can be important with respect to choice of adjunct mechanical or medical therapy, such as intra aortic balloon pumping (IABP), Gp IIb/IIIa inhibitors or continuation of nitroglycerine.
Despite this undisputed importance of microvascular perfusion and function in the acute phase of myocardial infarction, its assessment has been difficult so far and has been hampered by a number of methodological and technical shortcomings.It should be realized in this context that the function of the microvasculature in general (and specifically in acute myocardial infarction) can be characterized by myocardial blood flow and resistance.
Recently, the investigators have developed a new technique for measuring absolute coronary and myocardial blood flow and absolute and relative coronary and myocardial resistance This has paved the way to study microvascular function in acute myocardial infarction immediately after epicardial reperfusion by PPCI and in the days thereafter.
|Study Type :||Observational|
|Estimated Enrollment :||25 participants|
|Official Title:||Microvascular Dysfunction in AMI and Its Relation to Outcome|
|Study Start Date :||March 2012|
|Estimated Primary Completion Date :||October 2012|
|Estimated Study Completion Date :||October 2012|
|measurement absolute flow and resistance|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01538303
|Catharina Hospital Eindhoven||Recruiting|
|Eindhoven, Brabant, Netherlands, 5623EJ|
|Contact: Nico Pijls, MD,PhD 0031 40 2397004 email@example.com|
|Contact: Inge Wijnbergen, MD 0031 40 2397004 firstname.lastname@example.org|
|Sub-Investigator: Inge Wijnbergen, MD|
|Sub-Investigator: Marcel van 't Veer, PhD|
|Sub-Investigator: Pim Tonino, MD,PhD|
|Principal Investigator:||Nico Pijls, MD, PhD||Catharina Ziekenhuis Eindhoven|